No medications are approved for cannabis use disorder (CUD). Gamma-aminobutyric acid (GABA) reuptake is modulated by cannabinoid (CB) receptor agonists, and there are shared effects between CB agonists and the GABA reuptake inhibitor tiagabine. This overlapping neuropharmacology suggested that tiagabine might be useful for CUD. The study determined the ability of tiagabine maintenance to reduce cannabis selfadministration using a placebo-controlled, double-blind, counterbalanced, within-subjects design. Nontreatment-seeking daily cannabis users (N ϭ 12; 3 female, 9 male) completed two 12-day outpatient maintenance phases (0 or 12 mg of tiagabine/day). Each phase consisted of a safety session, 7 maintenance days, and 4 experimental sessions. During experimental sessions, maintenance continued and participants completed two 2-day blocks of sampling and self-administration sessions to determine the reinforcing effects of smoked cannabis (0% and 5.9% ⌬9-tetrahydrocannabinol). Naturalistic cannabis use, the subjective, performance and physiological response to cannabis, as well as side effects, sleep quality, craving, other self-reported substance use, and observer ratings were also measured. Cannabis functioned as a reinforcer and produced prototypical effects (e.g., increased heart rate and ratings of "high"), but tiagabine generally did not impact the effects of cannabis, or alter naturalistic use. Furthermore, tiagabine produced small, but significant, increases on 2 subscales of a Marijuana Craving Questionnaire, and reductions in both the amount of time slept in the past 24 hr and ratings of positive mood upon awakening. These human laboratory results from a sample of nontreatment-seeking cannabis users do not support the potential efficacy of 12 mg of tiagabine as a stand-alone pharmacotherapy for CUD.
The U.S. National Survey on Drug Use and Health estimated that daily or near-daily cannabis use increased by over 3 million people from 2007 to 2013 (Compton, Han, Jones, Blanco, & Hughes, 2016) . Current estimates indicate that 1.5% of the U.S. population meets cannabis use disorder (CUD) criteria, with cannabis being the primary drug of approximately 15% of all drug treatment admissions (Center for Behavioral Health Statistics & Quality, 2016a , 2016b . Given the dramatically changing landscape surrounding cannabis use in the United States, there are concerns that rates of cannabis use and the need for treatment will continue to rise. Over half of the states (29 of 50) have legalized medicinal cannabis use and eight states, plus Washington, DC, have legalized recreational use. One recent survey indicated that 53% of respondents favor some form of legalization, compared to just 32% in 2006 (Pew Research Center, 2015 . In addition, a recent analysis found that seized cannabis ⌬9-tetrahydrocannabinol (THC) concentrations increased from approximately 4% in 1995 4% in to 12% in 2014 4% in (ElSohly et al., 2016 , and strains of up to 30% THC are now commercially available, which could exacerbate incidence and prevalence of CUD. Considering existing treatment needs and the possibility of greater demand in the future, there is an emphasis on the development of pharmacotherapies to manage CUD (Gorelick, 2016; Vandrey & Haney, 2009) .
A rational strategy for the development of candidate medications for initial screening is to select compounds based on the neuropharmacology of cannabis. Prior research has found that gamma-aminobutyric acid (GABA) reuptake is inhibited by stimulation of presynaptic cannabinoid (CB 1 ) receptors on certain colocalized neurons (Maneuf, Nash, Crossman, & Brotchie, 1996; Romero, de Miguel, Ramos, & Fernández-Ruiz, 1998) , and also possibly by direct interaction of CB agonists with GABA transporters (Coull, Johnston, Pertwee, & Davies, 1997) . Consistent with these findings, comparisons across preclinical studies indicate that CB agonists and GABA reuptake inhibitors such as tiagabine have overlapping effects on measures of memory, motor activity, anxiety-like behaviors, and pain (Lile, Kelly, & Hays, 2012) . In separate clinical studies, both CB agonists and tiagabine alleviate anxiety (Glass, Uhlenhuth, Hartel, Schuster, & Fischman, 1980; Schwartz & Nihalani, 2006) and neuropathic pain, (Bestard & Toth, 2011; Todorov, Kolchev, & Todorov, 2005) , and improve sleep (Babson, Sottile, & Morabito, 2017; Steiger, 2007) . These results indicate that there is a functional link between these systems, and that CB agonists and GABA reuptake inhibitors share some behavioral and pharmacotherapeutic effects, which suggested that tiagabine might function as an "agonist-like" medication for CUD.
Only one prior study has examined tiagabine effects in cannabis users. In that study (Lile et al., 2012) , weekly cannabis users learned to discriminate 30 mg of THC and then the separate and combined effects of tiagabine (6 and 12 mg) and THC (5, 15, and 30 mg) were assessed. The 12-mg dose of tiagabine alone substituted for the THC discriminative stimulus and engendered similar subjective effects, and both tiagabine doses shifted the discriminative-stimulus and subjective effects of the lowest THC doses leftward/upward when combined. The shared interoceptive effects of tiagabine and THC in cannabis users are consistent with an agonist replacement approach to treating drug use disorders. In addition, the therapeutic effects of tiagabine on anxiety and disrupted sleep noted above could address these main symptoms of cannabis abstinence (Budney, Moore, Vandrey, & Hughes, 2003) . Considering these potentially beneficial characteristics of tiagabine, the primary objective of this study was to evaluate its ability to attenuate cannabis-use behaviors.
Method Participants
Adult men and women, ages 18 -50, who reported daily or near-daily cannabis use (i.e., at least 25 days per month of use as defined by Budney, Vandrey, Hughes, Moore, & Bahrenburg, 2007) and could speak and read English were recruited from the local community. Potential participants completed demographic, drug-use history, and medical history questionnaires, as well as medical screens. Individuals with a history of serious physical disease or Axis I disorders according to Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) criteria, other than nicotine and/or cannabis dependence, were excluded from participating. Further exclusion criteria included seeking treatment for drug use, medical screening outcomes outside normal ranges deemed clinically significant by the study physician, seizure disorder, and pregnancy in women. Participants were also excluded for having first-degree family history of either cardiovascular disease that resulted in premature death or seizure disorder. The institutional review board of the University of Kentucky Medical Center approved the study and the informed consent document. Participants provided informed consent after the procedures and risks were fully explained. The institutional review board of the University of Kentucky approved the study.
Twelve participants (1 Black female, 2 White females, 2 Black males, 7 White males) completed the experiment. They ranged in age from 19 to 33 years (M ϭ 26), in education from 9 to 17 years (M ϭ 14), and in body mass index from 18 to 35 kg (M ϭ 26). One of the three female subjects reported taking a hormonal contraceptive. Participants reported cannabis use on 26 -30 days per month (M ϭ 27), 1-7 uses per use day (M ϭ 4), 1-13 "puffs" per use instance (M ϭ 6), and endorsed between one and four DSM-IV cannabis dependence items (M ϭ 2). At the time of screening, participants reported consuming standard alcohol-containing beverages on 0 to 7 days per week (M ϭ 2); none of the participants met DSM-IV criteria for alcohol dependence. Six participants reported using 2 to 20 tobacco cigarettes per day (M ϭ 3). Participants reported histories of other lifetime nonmedical drug use, though not in the month prior to screening. All participants provided a urine sample positive for recent cannabis use and negative for other recent substance use prior to study initiation.
Design
This study used a placebo-controlled, double-blind, tiagabineand cannabis-dose counterbalanced, within-subjects design. Participants were enrolled as outpatients at the University of Kentucky. They attended two practice sessions prior to completing two 12-day tiagabine maintenance phases (4 mg administered three times per day for a total daily dose of 12 mg, or placebo), as outlined in Table 1 . Each maintenance phase began on a Monday and ended on the Friday of the following week, with a 9-day interphase interval. Each phase consisted of an initial safety sesThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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sion (Monday), 7 maintenance-only days (Tuesday through the following Monday), and four experimental sessions (Tuesday through Friday). During experimental sessions, maintenance continued and participants completed two 2-day blocks of sampling and self-administration sessions to determine the reinforcing effects of cannabis (0% and 5.9% THC). Cannabis self-administration was chosen as the primary outcome because the ability of a medication to attenuate the reinforcing effects of abused drugs in laboratory studies is predictive of therapeutic efficacy (Comer et al., 2008; Haney & Spealman, 2008) .
General Procedures
Participants were required to abstain from illicit drugs other than cannabis throughout participation. Daily urine tests to assess recent drug use and pregnancy were negative throughout. Participants were also asked to avoid any over-the-counter medication, with the exception of nonsteroidal anti-inflammatory analgesics.
Maintenance days. On maintenance-only days (Days 2-8 and 14 -20), participants completed online questionnaires to assess recent activities, sleep, side effects, and drug use, and staff completed an Observer Rating Questionnaire. Participants were administered the first of the three daily tiagabine doses, and were given two "take-home" doses. Participants did not report to the laboratory on weekends. On Fridays, participants received an additional six take-home capsules, and they completed the online questionnaires remotely. Maintenance day attendance was reinforced with a US$5 payment that increased by $5 across each visit. Failure to attend a visit reset the value to $5.
Tiagabine dosing adherence outside of the laboratory (i.e., presumptive dosing) was monitored via Wisepill® technology, which makes use of mobile phone and Internet technologies to provide real-time medication management. If a participant missed a maintenance dose, she or he would have been permitted to restart that maintenance condition a single time; this occurred for one participant.
Abstinence reinforcement procedures. To simulate the motivation to quit using cannabis, and in an effort to enhance the ability to detect tiagabine effects on naturalistic cannabis use, participants were incentivized to abstain from cannabis use on maintenance days prior to experimental cannabis administration during sampling and self-administration sessions. Urine samples were obtained on study Days 1 (Phase 1 baseline), 3-5, 8 -9, 13 (Phase 2 baseline), 15-17, and 20 -21, and then submitted to Quest Diagnostics. Abstinence was determined by assaying urine samples for the THC metabolite 11-nor-9-carboxy-⌬ 9 -THC (THC-COOH) and creatinine (see Table 1 ). A ratio of at least 0.5 between the values of sequential creatinine-normalized THC-COOH results was considered indicative of abstinence (Huestis & Cone, 1998; Smith, Barnes, & Huestis, 2009 ) for the purpose of determining whether a participant qualified for an incentive. Whenever a participant submitted a sample negative for new use, she or he received $15, for total possible abstinence earnings of $150. Creatinine-normalized THC-COOH levels, instead of samples coded as positive or negative for new use, were analyzed in an effort to enhance the ability to detect an effect of tiagabine on naturalistic cannabis use by using a continuous, instead of a dichotomous, outcome variable.
Sessions. Practice, safety, and experimental (i.e., sampling and self-administration) sessions were conducted on weekdays and lasted 6.5 hr. Participants were asked to refrain from food, caffeine, alcohol, tobacco, and cannabis use prior to arrival. At intake, a breath sample was obtained to assess recent alcohol use. Participants also completed a field sobriety test and were observed by the research staff for cannabis intoxication (e.g., bloodshot, glassy eyes); none was detected during intake. Participants were provided, and were required to consume, a low-fat snack at intake. Participants who smoked tobacco cigarettes were also asked to abstain from smoking the morning of each session, but were allowed to smoke a single tobacco cigarette upon arrival to the laboratory to avoid testing under conditions of nicotine withdrawal. They were not allowed to smoke again until the session had ended. The maintenance-day questionnaires and dosing procedures described above were also completed during sessions.
Participants were reassessed at the end of the session for possible intoxication and/or impairment using the field sobriety test prior to release. In addition, participants were required to report no 
Note. The order of tiagabine maintenance dose and percentage ⌬9-tetrahydrocannabinol concentration is representative. THC ϭ ⌬9-tetrahydrocannabinol; Maint ϭ maintenance; Self-admin ϭ self-administration. The checkmark indicates days on which urine samples were collected for semi-quantitative urinalysis.
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further drug effects. If necessary, participants were retained at the laboratory beyond the scheduled session time until residual drug effects dissipated. Participants were compensated $50 for completing each session and received an additional $50 per session if they completed the entire study. Practice sessions. A first practice session matched a sampling session and the second a self-administration session. Participants smoked unblinded placebo cannabis cigarettes to become acquainted with the paced smoking procedure (Foltin, Brady, Fischman, Emurian, & Dominitz, 1987) . On the practice self-administration session, participants were required to work to receive the maximum number of puffs (eight) to familiarize them with the response requirements.
Safety session. On the first day of each maintenance phase, participants received the first tiagabine maintenance dose and were monitored for adverse events, but none occurred. Participants completed the session outcome measures described below, but the data are not reported.
Sampling sessions. Study Days 9, 11, 21, and 23 were sampling sessions (i.e., one for each tiagabine and cannabis dose combination), which were conducted to familiarize participants with the effects of the cannabis they could work for in a subsequent session . One hour after maintenance dosing, participants received four puffs from two cigarettes (i.e., eight total puffs); this delay was imposed to account for the time allowed to complete the self-administration task in the subsequent session and keep the different sessions types on a similar timeline. Participants were instructed to pay attention to the effects of the cannabis, as they would be given the opportunity to work to receive puffs from the same cannabis condition in the next session.
Self-administration sessions. Study Days 10, 12, 22, and 24 were self-administration sessions. Immediately after maintenance dosing, participants could respond on a selfadministration task by "clicking" a computer mouse to earn up to eight puffs of cannabis on a fixed-ratio 1,000 schedule. To earn the maximum number of puffs, participants were required to emit 8,000 mouse "clicks." Once the task was complete, the participants self-administered the number of puffs earned using the paced smoking procedure.
Outcome Measures
Sessions. In addition to the primary outcome (i.e., self-administered puffs), the following secondary measures were obtained. Because the number of cannabis puffs varied on self-administration sessions, only results from secondary measures obtained on sampling sessions are reported. Data were collected in fixed order, prior to, and following, cannabis administration for 4 hr, at regular intervals, which varied by outcome measure (see below). Except for temperature assessments, data were collected on an Apple Macintosh computer (Apple Computer, Inc., Cupertino, CA).
A 20-item, 100-unit Visual Analog Scale (VAS) SubjectRated Drug-Effect Questionnaire (Lile et al., 2012) was administered 1 hr prior to, immediately following, and 15, 30, 45, 60, 90, 120, 180 , and 240 min after cannabis administration. At the end of the session, participants also completed a Street Value Questionnaire. A performance task battery was collected 1 hr prior to, immediately following, and 30, 60, 90, 120, 180, and 240 min after cannabis administration, and included a Repeated Acquisition of Response Sequences Task (RA task), a DigitSymbol-Substitution Test, and a Time Reproduction Task (Heishman, Stitzer, & Yingling, 1989; Kelly, Foltin, Emurian, & Fischman, 1990 , 1993 Lile et al., 2012; Wilson, Ellinwood, Mathew, & Johnson, 1994) . Heart rate, blood pressure, skin temperature, and oral temperature were measured immediately prior to, and 15, 45, 60, 90, 120, 180 , and 240 min after, cannabis administration (Lile at al., 2012) .
Maintenance days. Participants were asked whether they had experienced 35 of the most common and/or serious side effects of tiagabine (Cephalon, Inc., Frazer, PA) and cannabis withdrawal (Budney et al., 2003) . If a side effect item was endorsed, participants were asked to indicate the severity (mild, moderate, or severe) and whether they felt it was due to the study medication. Participants also reported standard alcohol drinks consumed, cigarettes smoked, times cannabis was used, and puffs taken in the past 24 hr. Participants were also asked about other drug use, but none was reported, consistent with urine drug screen results. Participants completed the 12-item version of the Marijuana Craving Questionnaire (MCQ; Heishman et al., 2009) , and a past 24-hr sleep questionnaire to determine minutes to fall asleep, hours asleep, times awake in the night, and whether a sleep aid was used. Participants also rated sleep quality, and positive mood and alertness upon awakening (Vandrey et al., 2013) .
The Observer Rating Questionnaire is a locally developed VAS scale that includes eight items (the participant appears: anxious, sedated, confused, physically unstable; the participant is having: difficulty concentrating, difficulty communicating, abnormal/erratic behavior; and overall impairment).
Drug Administration
Cannabis cigarettes (0% and 5.9% THC) were provided by the National Institute on Drug Abuse. Prior to cannabis administration, heart rate was assessed. If heart rate exceeded 100 beats per minute (bpm), cannabis administration would have been withheld, but this did not occur.
Tiagabine (0 and 4 mg) was administered in one opaque capsule containing commercially available Gabitril® (Cephalon, Inc., Frazer, PA) three times per day. Cornstarch was used to backfill the capsules, and placebo capsules contained only cornstarch. For reference, the recommended initial tiagabine dose for the management of epilepsy is 4 mg/day as a single dose, with titration at weekly intervals by 4 -8 mg up to 56 mg in two to four divided doses in patients who are taking hepatic enzyme-inducing agents (Cephalon, Inc., Frazer, PA) . However, the systemic clearance of tiagabine in induced patients is approximately 60% greater than noninduced patients, so lower doses (12-22 mg) are indicated in noninduced individuals (i.e., the participants in the present study). The 12-mg daily tiagabine dose was selected for the present study because it struck a balance between safety and anticipated efficacy based on the dosing recommendations for epilepsy, our prior findings from the study in cannabis users that used acute tiagabine and THC dosing procedures (Lile et al., 2012) , and the limitations of the study design (i.e., within-subjects, 7 maintenance-only days, no titration period). This document is copyrighted by the American Psychological Association or one of its allied publishers.
Data Analyses
To account for the correlation among repeated measures, generalized estimating equations with random participant effect (or an exchangeable correlation) were used to fit a linear model for each outcome. For binary outcomes, in which marginal probabilities were of interest, an identity link was incorporated in the model while utilizing a marginal Bernoulli distribution. Fixed effects for tiagabine and cannabis, as well as their interaction, were used as predictors. Significant interactions were followed with post hoc pairwise comparisons; otherwise, main effects are reported. Session data having multiple time points were analyzed as means and peak effects after cannabis administration; results were comparable so only mean results are reported. For maintenance-day outcomes, tiagabine was the only predictor. Small-sample corrected standard errors were utilized with between-within degrees of freedom. All tests were two sided and utilized a 5% significance level. Analyses were conducted in SAS (version 9.4).
Results
Model estimates and 95% confidence intervals for outcome measures for which a significant main effect or interaction was observed are in Table 2 .
Cannabis Self-Administration
Participants self-administered a significantly greater number of puffs of smoked cannabis containing active THC (p Ͻ .001) compared to placebo, but the number of puffs did not vary by tiagabine condition (see Figure 1 ).
Subject Ratings
A significant main effect of cannabis was found for 12 VAS items: Any Effect, Good Effects, High, Stoned, Anxious, Like Drug, Stimulated, Take Again, Pay For, Dizzy/Lightheaded, Thirsty, and Forgetful (ps Յ .05). Active cannabis significantly increased ratings on these items relative to placebo, but these ratings were not impacted by tiagabine. A significant main effect of tiagabine (p ϭ .04) was found for Any Effect; active tiagabine increased ratings on this item. Any Effect and High are presented in Figure 1 .
A significant main effect of cannabis (p Ͻ .001) was observed on the Street Value Questionnaire. Active cannabis increased the value of the dose relative to placebo, but values were unaffected by tiagabine (see Figure 1 ).
Performance
A significant interaction between cannabis and tiagabine was found for the number of chains completed and total responses on the acquisition component of the RA task (ps ϭ 0.01). Rate and accuracy were significantly improved by active tiagabine when measured following placebo cannabis administration (see Figure  2 ). An interaction of cannabis and tiagabine was detected on the reproduction of 60-s time interval (p ϭ .03) but post hoc analysis did not reveal differences.
Heart Rate, Blood Pressure, and Temperature
Active cannabis significantly elevated heart rate (p Ͻ .001), but tiagabine had no effect on heart rate when administered in combination with active or placebo cannabis. When collapsed across tiagabine dose, mean heart rate increased to 71.1 bpm (SEM ϭ 3.9) after active cannabis compared to 65.5 bpm (SEM ϭ 3.4) following placebo.
Naturalistic Cannabis, Alcohol, and Tobacco Cigarette Use
The abstinence incentive value was changed based on initial feedback, so the first participant's cannabis use data were omitted. Occasionally, laboratory visits were cancelled (e.g., holidays and weather), resulting in 8 out of 132 missed urine samples (4 in each of the two maintenance conditions). Creatinine-normalized levels of urine THC-COOH were not significantly impacted by tiagabine (see Figure 3) . Coincidentally, the same number of urine samples (18 of 62; 29%) was negative for new cannabis use in both the placebo and active tiagabine maintenance conditions. None of the participants maintained abstinence throughout either of the maintenance phases, as assessed prior to the experimental administration of cannabis using semi-quantitative urinalysis. Self-reported cannabis use was also not impacted by tiagabine, though participants tended to deny recent use, making further reductions in self-reported use difficult to detect. Past 24-hr use of alcohol and tobacco also did not differ by tiagabine condition. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Side Effects
There was a zero incidence rate for 29 of 35 side effects in at least one of the maintenance conditions, so statistical analysis was not conducted. Instead, side effects attributed to study medication that occurred at a rate Ͼ5% (i.e., at least 7 out of 144 possible counts per side effect) are noted. Participants reported muscle weakness of mild-to-moderate severity on seven occasions during 12-mg tiagabine maintenance and no occasions during placebo. Participants also reported strange dreams of mild or moderate 
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Accuracy and rate on the RA task significantly improved in the active tiagabine ϩ placebo cannabis condition. Other details are as in Figure 1 . This document is copyrighted by the American Psychological Association or one of its allied publishers.
severity on seven occasions during tiagabine maintenance and four occasions during placebo. No severe side effects were noted.
MCQ-SF
Active tiagabine significantly (ps ϭ .02) increased scores on the Compulsivity and Purposefulness scales of the MCQ (see Figure 4) .
Sleep
A main effect of tiagabine was found for two of the seven sleep outcomes of interest. As shown in Figure 4 , 12 mg of daily tiagabine significantly (p ϭ .004) decreased the average number of hours of sleep and reduced positive mood upon awakening (p ϭ .01).
Observer Rating Questionnaire
Because the majority of the responses had a zero value, data were analyzed as the probability of having a value of Ͼ 0. Active tiagabine significantly increased the likelihood of having a nonzero score on staff ratings of participants appearing anxious (p ϭ .05) and confused (p ϭ .05).
Discussion
The aim of this study was to conduct an initial assessment of tiagabine as a medication for CUD by maintaining habitual cannabis users on tiagabine on an outpatient basis in order to determine its effects on cannabis self-administration in the laboratory and use in the natural environment. A similarly designed hybrid outpatient maintenance and laboratory study with nontreatmentseeking participants yielded promising results with naltrexone (Haney et al., 2015) , and further supported the assertion that changes in laboratory drug self-administration translates to naturalistic use. A notable difference is that incentives for cannabis abstinence were not included in the study by Haney and colleagues. The incentives included here were expected to enhance the ability to detect therapeutic effects of tiagabine on naturalistic use. However, tiagabine did not significantly impact laboratory self-administration, creatinine-normalized THC-COOH levels, or the number of urine samples negative for new cannabis use. Together, these results suggest that a valid screening procedure was used, but that tiagabine is unlikely to be effective as a stand-alone treatment for CUD by reducing the reinforcing effects of cannabis.
With the exception of the item Any Effect, tiagabine also did not significantly affect the subjective effects of cannabis in the present study. In our prior study, however, 6 and 12 mg of acutely administered tiagabine enhanced drug-appropriate responding on a drug discrimination task and peak ratings on most subjective effects questionnaire items increased by 5 and 15 mg of THC (Lile et al., 2012) . Neither dose of tiagabine altered the peak subjective ratings of 30 mg THC (ϳ50 -70 out of 100 on a VAS) on THC-sensitive items, suggesting a ceiling on the ability of tiagbine to modify the interoceptive effects of cannabinoid agonists. Con- This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
sistent with that finding, peak VAS ratings for most cannabissensitive items were in a comparable range following administration of the 5.9% THC cannabis in the present study (data not shown). Although that explanation is possible, we predicted that tiagabine maintenance would attenuate the subjective response to cannabis, rather than enhance it. This prediction was based on prior human laboratory studies that tested agonist replacement medications (i.e., compounds that shared a mechanism of action and had overlapping subjective and discriminative-stimulus effects with the abused drug) with demonstrated efficacy in clinical trials (Donny, Brasser, Bigelow, Stitzer, & Walsh, 2005; Rush, Stoops, & Hays, 2009; Sobel, Sigmon, & Griffiths, 2004) . Those studies found that that the subjective effects of the abused drug were diminished during maintenance, possibly via tolerance. In this study, however, tiagabine did not produce an analogous attenuation of the subjective response to cannabis that would have been characteristic of an agonist replacement medication. One possibility is that treatment with a compound having a common direct mechanism of action (i.e., another cannabinoid receptor ligand) would be needed to alter the subjective effects of cannabis and that maintenance on a drug having shared interoceptive effects, which might be the result of downstream receptor actions (e.g., tiagabine), is not sufficient. Another possibility is that the dose of tiagabine was too low to alter the effects of cannabis or change naturalistic cannabis use. The 12-mg dose of tiagabine is at the lower end of the range recommended for patients who are not concurrently prescribed hepatic enzyme-inducing medications. Nonetheless, this relatively low dose of tiagabine produced a profile of effects indicative of biological activity but not therapeutic efficacy. During active tiagabine maintenance, participants reported increased ratings of Any Effect in experimental sessions, and more cannabis craving, less sleep, and reduced positive mood upon awakening. In addition, the research staff rated participants as more anxious and confused during active tiagabine.
The only outcome demonstrating a Tiagabine ϫ Cannabis effect was the Repeated Acquisition task. During active tiagabine maintenance, rate and accuracy on the RA task were improved during placebo cannabis sessions. Tiagabine did not influence RA task performance following 5.9% THC cannabis administration, suggesting that cannabis-induced impairment might have offset the performance-enhancing effects of tiagabine. These results contrast with our prior study in which tiagabine significantly impaired RA task performance (Lile et al., 2012) , but are in agreement with varying tiagabine effects as a function of acute versus maintenance dosing.
Considering that the majority of cannabis-sensitive outcomes were unaffected by tiagabine, and that the effects of tiagabine were of low magnitude and detected on only a few maintenance day assessments, a follow-up study was initiated to evaluate 18 mg/day administered as 9 mg twice daily following 4 days of dose escalation. Three participants completed that protocol without incident, but one participant experienced an adverse event following controlled administration of active cannabis during active tiagabine maintenance. That participant experienced side effects rated from mild to severe that included altered mood, nausea, vomiting, muscle dysfunction, dizziness, change in temperature sensations, tingling in extremities, and dry/metallic taste. The participant was discontinued from further participation and followed until resolution. Unrelated to this event, the U.S. Food and Drug Administration expressed concerns about the protocol, in particular the dose escalation schedule, which was more rapid than recommended in the tiagabine product information, and required that the design be altered so that the dose escalation procedure matched manufacturer recommendations in order for the study to continue. Unfortunately, such a design would have required at least 4 weeks of dose escalation prior to laboratory testing of cannabis self-administration, which was not feasible given time and budget restraints. Consequently, the study was closed.
A limitation of this study is that the laboratory self-administration procedure did not include an alternative reinforcer, which might have increased the likelihood of detecting a reduction in cannabis reinforcement (Banks & Negus, 2017) . However, naturalistic use, as determined by urine CB levels, occurred in an environment with a myriad of alternatives, but was also not impacted by tiagabine. Another limitation is that the method of determining recent abstinence based on urine CB levels was developed in less frequent cannabis users (Huestis & Cone, 1998; Smith et al., 2009 ). A newer model for determining new use in daily users has since been established, (Schwilke et al., 2011) but that model requires sample collection across a longer period that was incompatible with this study design. Although the earlier method was used for determining whether abstinence incentives were given, the creatinine-to-THC-COOH ratios were used in the present analyses to determine whether tiagabine impacted naturalistic cannabis use. A third limitation is that participants were asked to refrain from caffeine use on the morning of sessions. This study requirement was imposed to avoid interactions with experimentally administered cannabis, as has been done in prior research, but creates an artificial situation that might not generalize to typical cannabis use scenarios.
Other drugs that increase central GABA levels, albeit through different mechanisms, have been tested as potential medications for CUD. For example, valproic acid (as divalproex sodium, a 1:1 compound of valproic acid and its sodium salt), which inhibits the metabolic enzyme GABA transaminase (but see Rosenberg, 2007 , for other potential mechanisms), has been evaluated in a human laboratory model of cannabis withdrawal and in a controlled clinical trial (Haney et al., 2004; Levin et al., 2004) . Although divalproex sodium decreased craving for cannabis in the laboratory study, it also worsened mood and cognitive performance, and was ineffective at reducing cannabis use in the clinical trial. Gabapentin has also been evaluated as a potential CUD medication. A 12-week pilot clinical trial demonstrated that treatment with 1,200 mg/day gabapentin was significantly more effective at reducing cannabis use and improving craving, depression, and sleep quality than placebo (Mason et al., 2012) . Although the therapeutic effects of gabapentin have been linked primarily to voltage-dependent calcium channels (VDCCs), particularly those containing ␣ 2 ␦-1 subunits, there is also evidence that it elevates brain GABA levels (Cai et al., 2012) . However, the negative results from the present study with tiagabine and the previous studies with valproic acid suggest that the initial efficacy of gabapentin might be linked to its VDCC mechanism rather than its ability to elevate brain GABA levels.
In conclusion, maintenance on 12 mg of tiagabine did not alter cannabis self-administration or cannabis use in the natural environment in nontreatment-seeking daily cannabis users. In addition, tiagabine worsened some measures of sleep and cannabis craving, indicating that it would not be useful for managing these main This document is copyrighted by the American Psychological Association or one of its allied publishers.
symptoms of cannabis withdrawal. Administration of a higher tiagabine dose resulted in a significant adverse event when combined with cannabis in one of four participants, although important to note is that a more rapid dose-escalation procedure than what is clinically recommended was used. These experimental results do not support the continued evaluation of tiagabine as a stand-alone pharmacotherapy for CUD.
